9 minute read
Aug. 4, 2023
A pioneering oral OX2R agonist from Takeda for treatment of narcolepsy.
TAK-994
oral, brain-penetrant OX2R agonist Ph. II for narcolepsy; discontinued for safety signal from prior OX2R agonists derived from HTS J. Pharm. Exp. Ther., May 17, 2023 TAKEDA, FUJISAWA, JP
Loading...
